How is myeloma treatment personalized for varying levels of fitness and frailty?

How is myeloma treatment personalized to genetic markers now and what may the future of precision medicine in myeloma be?

What is precision medicine?

Will del 17p and other chromosomal abnormalities go away after an auto ASCT? If not why may it not be detected?

What is a 17p deletion? Why is del of 17p considered high risk?

Why is chromosome 14 a site of high-risk myeloma genetics? What is the job of chromosome 14?

(Guest Lecture): Balancing Today with Tomorrow’s Opportunity | MCRT Webcast: Why Physicians Are Optimistic About Newly Diagnosed Myeloma

(Guest Lecture): A Discussion of Two Case Studies | MCRT Webcast: Why Physicians Are Optimistic About Newly Diagnosed Myeloma

(Guest Lecture): An Increasing Arsenal of Therapeutic Options | MCRT Webcast: Why Physicians Are Optimistic About Newly Diagnosed Myeloma

(Guest Lecture): The Ever-Changing Landscape of Treatment | MCRT Webcast: Why Physicians Are Optimistic About Newly Diagnosed Myeloma

What chromosomal abnormalities are considered high-risk, standard risk?

What is the definition of high-risk multiple myeloma (HRMM)?